{
    "id": 25149,
    "fullName": "EGF positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGF positive indicates the presence of the EGF gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1950,
        "geneSymbol": "EGF",
        "terms": [
            "EGF",
            "HOMG4",
            "URG"
        ]
    },
    "variant": "positive",
    "createDate": "08/10/2016",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7717,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, vaccination with CIMAvax-EGF demonstrated safety, and resulted in a median survival time of 12.43 months in patients with advanced non-small cell lung cancer, compared to 9.43 months in nonvaccinated patients, and a 5-year survival rate of 16.62% vs 6.2% in nonvaccinated patients (PMID: 26927662).",
            "molecularProfile": {
                "id": 25930,
                "profileName": "EGF positive"
            },
            "therapy": {
                "id": 4551,
                "therapyName": "CIMAvax-EGF",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6453,
                    "pubMedId": 26927662,
                    "title": "A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26927662"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25930,
            "profileName": "EGF positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}